Using  ||| S:0 E:6 ||| VBG
non-steroidal  ||| S:6 E:20 ||| JJ
anti-inflammatory  ||| S:20 E:38 ||| JJ
drugs  ||| S:38 E:44 ||| NNS
in  ||| S:44 E:47 ||| IN
the  ||| S:47 E:51 ||| DT
treatment  ||| S:51 E:61 ||| NN
of  ||| S:61 E:64 ||| IN
depression  ||| S:64 E:75 ||| NN
clinicians  ||| S:75 E:86 ||| NNS
have  ||| S:86 E:91 ||| VBP
long  ||| S:91 E:96 ||| RB
noticed  ||| S:96 E:104 ||| VBD
a  ||| S:104 E:106 ||| DT
correlation  ||| S:106 E:118 ||| NN
between  ||| S:118 E:126 ||| IN
physiological  ||| S:126 E:140 ||| JJ
markers  ||| S:140 E:148 ||| NN
of  ||| S:148 E:151 ||| IN
inflammation  ||| S:151 E:164 ||| NN
and  ||| S:164 E:168 ||| CC
depression ||| S:168 E:178 ||| NN
.  ||| S:178 E:180 ||| .
The  ||| S:180 E:184 ||| DT
best-known  ||| S:184 E:195 ||| JJS
example  ||| S:195 E:203 ||| NN
is  ||| S:203 E:206 ||| VBZ
the  ||| S:206 E:210 ||| DT
activation  ||| S:210 E:221 ||| NN
of  ||| S:221 E:224 ||| IN
the  ||| S:224 E:228 ||| DT
hypothalamus-pituitary-adrenal  ||| S:228 E:259 ||| JJ
axis  ||| S:259 E:264 ||| NN
and  ||| S:264 E:268 ||| CC
cortisol  ||| S:268 E:277 ||| JJ
secretion ||| S:277 E:286 ||| NN
;  ||| S:286 E:288 ||| :
however  ||| S:288 E:296 ||| RB
more  ||| S:296 E:301 ||| RBR
recent  ||| S:301 E:308 ||| JJ
studies  ||| S:308 E:316 ||| NNS
have  ||| S:316 E:321 ||| VBP
demonstrated  ||| S:321 E:334 ||| VBN
increased  ||| S:334 E:344 ||| VBN
salivary  ||| S:344 E:353 ||| JJ
prostaglandins  ||| S:353 E:368 ||| NN
and  ||| S:368 E:372 ||| CC
plasma  ||| S:372 E:379 ||| JJ
acute  ||| S:379 E:385 ||| JJ
phase  ||| S:385 E:391 ||| NN
proteins  ||| S:391 E:400 ||| NNS
in  ||| S:400 E:403 ||| IN
depressed  ||| S:403 E:413 ||| JJ
patients ||| S:413 E:421 ||| NNS
.  ||| S:421 E:423 ||| .
To  ||| S:423 E:426 ||| TO
date  ||| S:426 E:431 ||| VB
four  ||| S:431 E:436 ||| CD
randomised  ||| S:436 E:447 ||| NNS
controlled  ||| S:447 E:458 ||| VBN
trials  ||| S:458 E:465 ||| NNS
have  ||| S:465 E:470 ||| VBP
used  ||| S:470 E:475 ||| VBN
celecoxib  ||| S:475 E:485 ||| NNS
or  ||| S:485 E:488 ||| CC
rofecoxib  ||| S:488 E:498 ||| NN
as  ||| S:498 E:501 ||| IN
adjuncts  ||| S:501 E:510 ||| VBG
to  ||| S:510 E:513 ||| TO
serotonin  ||| S:513 E:523 ||| VB
selective  ||| S:523 E:533 ||| JJ
reuptake  ||| S:533 E:542 ||| JJ
inhibitors  ||| S:542 E:553 ||| NN
in  ||| S:553 E:556 ||| IN
the  ||| S:556 E:560 ||| DT
treatment  ||| S:560 E:570 ||| NN
of  ||| S:570 E:573 ||| IN
depression ||| S:573 E:583 ||| NN
.  ||| S:583 E:585 ||| .
These  ||| S:585 E:591 ||| DT
suggested  ||| S:591 E:601 ||| VBD
a  ||| S:601 E:603 ||| DT
statistically  ||| S:603 E:617 ||| JJ
significant  ||| S:617 E:629 ||| JJ
decrease  ||| S:629 E:638 ||| NN
in  ||| S:638 E:641 ||| IN
depressive  ||| S:641 E:652 ||| JJ
symptoms  ||| S:652 E:661 ||| NNS
in  ||| S:661 E:664 ||| IN
the  ||| S:664 E:668 ||| DT
patients  ||| S:668 E:677 ||| NNS
taking  ||| S:677 E:684 ||| VBG
NSAIDs  ||| S:684 E:691 ||| JJ
and  ||| S:691 E:695 ||| CC
SSRIs ||| S:695 E:700 ||| JJ
,  ||| S:700 E:702 ||| ,
compared  ||| S:702 E:711 ||| VBN
to  ||| S:711 E:714 ||| TO
patients  ||| S:714 E:723 ||| NNS
taking  ||| S:723 E:730 ||| VBG
SSRIs  ||| S:730 E:736 ||| JJ
alone ||| S:736 E:741 ||| RB
.  ||| S:741 E:743 ||| .
Interpretation  ||| S:743 E:758 ||| NN
of  ||| S:758 E:761 ||| IN
these  ||| S:761 E:767 ||| DT
results  ||| S:767 E:775 ||| NNS
is  ||| S:775 E:778 ||| VBZ
limited  ||| S:778 E:786 ||| VBN
by  ||| S:786 E:789 ||| IN
the  ||| S:789 E:793 ||| DT
small  ||| S:793 E:799 ||| JJ
sample  ||| S:799 E:806 ||| NN
size  ||| S:806 E:811 ||| NN
and  ||| S:811 E:815 ||| CC
short  ||| S:815 E:821 ||| JJ
duration  ||| S:821 E:830 ||| NN
of  ||| S:830 E:833 ||| IN
these  ||| S:833 E:839 ||| DT
preliminary  ||| S:839 E:851 ||| JJ
studies ||| S:851 E:858 ||| NNS
.  ||| S:858 E:860 ||| .
The  ||| S:860 E:864 ||| DT
research  ||| S:864 E:873 ||| NN
only  ||| S:873 E:878 ||| RB
considers  ||| S:878 E:888 ||| VBZ
depressed  ||| S:888 E:898 ||| JJ
patients  ||| S:898 E:907 ||| NNS
receiving  ||| S:907 E:917 ||| VBG
treatment  ||| S:917 E:927 ||| NN
in  ||| S:927 E:930 ||| IN
secondary  ||| S:930 E:940 ||| JJ
care ||| S:940 E:944 ||| NN
;  ||| S:944 E:946 ||| :
no  ||| S:946 E:949 ||| DT
study  ||| S:949 E:955 ||| NN
has  ||| S:955 E:959 ||| VBZ
examined  ||| S:959 E:968 ||| VBN
the  ||| S:968 E:972 ||| DT
effectiveness  ||| S:972 E:986 ||| NN
of  ||| S:986 E:989 ||| IN
NSAIDs  ||| S:989 E:996 ||| JJ
as  ||| S:996 E:999 ||| IN
an  ||| S:999 E:1002 ||| DT
adjunct  ||| S:1002 E:1010 ||| NN
in  ||| S:1010 E:1013 ||| IN
primary  ||| S:1013 E:1021 ||| JJ
care ||| S:1021 E:1025 ||| NN
,  ||| S:1025 E:1027 ||| ,
even  ||| S:1027 E:1032 ||| RB
though  ||| S:1032 E:1039 ||| IN
most  ||| S:1039 E:1044 ||| JJS
cases  ||| S:1044 E:1050 ||| NNS
of  ||| S:1050 E:1053 ||| IN
depression  ||| S:1053 E:1064 ||| NN
in  ||| S:1064 E:1067 ||| IN
the  ||| S:1067 E:1071 ||| DT
UK  ||| S:1071 E:1074 ||| NNP
are  ||| S:1074 E:1078 ||| VBP
managed  ||| S:1078 E:1086 ||| VBN
in  ||| S:1086 E:1089 ||| IN
the  ||| S:1089 E:1093 ||| DT
community  ||| S:1093 E:1103 ||| NN
by  ||| S:1103 E:1106 ||| IN
general  ||| S:1106 E:1114 ||| JJ
practitioners.  ||| S:1114 E:1129 ||| NN
we  ||| S:1129 E:1132 ||| PRP
propose  ||| S:1132 E:1140 ||| VBP
a  ||| S:1140 E:1142 ||| DT
multi-centre  ||| S:1142 E:1155 ||| JJ
double-blinded  ||| S:1155 E:1170 ||| JJ
randomised  ||| S:1170 E:1181 ||| NNS
controlled  ||| S:1181 E:1192 ||| VBN
trial  ||| S:1192 E:1198 ||| NN
with  ||| S:1198 E:1203 ||| IN
two  ||| S:1203 E:1207 ||| CD
objectives ||| S:1207 E:1217 ||| NNS
:  ||| S:1217 E:1219 ||| :
to  ||| S:1219 E:1222 ||| TO
determine  ||| S:1222 E:1232 ||| VB
whether  ||| S:1232 E:1240 ||| IN
citalopram  ||| S:1240 E:1251 ||| NN
plus  ||| S:1251 E:1256 ||| CC
celecoxib  ||| S:1256 E:1266 ||| JJ
dual  ||| S:1266 E:1271 ||| JJ
therapy  ||| S:1271 E:1279 ||| NN
achieves  ||| S:1279 E:1288 ||| VBZ
a  ||| S:1288 E:1290 ||| DT
greater  ||| S:1290 E:1298 ||| JJR
reduction  ||| S:1298 E:1308 ||| NN
in  ||| S:1308 E:1311 ||| IN
depressive  ||| S:1311 E:1322 ||| JJ
symptoms  ||| S:1322 E:1331 ||| NNS
( ||| S:1331 E:1332 ||| -LRB-
quantified  ||| S:1332 E:1343 ||| VBN
using  ||| S:1343 E:1349 ||| VBG
the  ||| S:1349 E:1353 ||| DT
Hamilton  ||| S:1353 E:1362 ||| NNP
Depression  ||| S:1362 E:1373 ||| NNP
Rating  ||| S:1373 E:1380 ||| NNP
Scale  ||| S:1380 E:1386 ||| NNP
( ||| S:1386 E:1387 ||| -LRB-
HDRS ||| S:1387 E:1391 ||| NNP
) ||| S:1391 E:1392 ||| -RRB-
)  ||| S:1392 E:1394 ||| -RRB-
within  ||| S:1394 E:1401 ||| IN
four  ||| S:1401 E:1406 ||| CD
weeks ||| S:1406 E:1411 ||| NNS
,  ||| S:1411 E:1413 ||| ,
compared  ||| S:1413 E:1422 ||| VBN
to  ||| S:1422 E:1425 ||| TO
citalopram  ||| S:1425 E:1436 ||| VB
monotherapy ||| S:1436 E:1447 ||| NNS
;  ||| S:1447 E:1449 ||| :
and  ||| S:1449 E:1453 ||| CC
to  ||| S:1453 E:1456 ||| TO
determine  ||| S:1456 E:1466 ||| VB
whether  ||| S:1466 E:1474 ||| IN
citalopram  ||| S:1474 E:1485 ||| NN
plus  ||| S:1485 E:1490 ||| CC
celecoxib  ||| S:1490 E:1500 ||| JJ
dual  ||| S:1500 E:1505 ||| JJ
therapy  ||| S:1505 E:1513 ||| NN
is  ||| S:1513 E:1516 ||| VBZ
more  ||| S:1516 E:1521 ||| RBR
likely  ||| S:1521 E:1528 ||| JJ
to  ||| S:1528 E:1531 ||| TO
achieve  ||| S:1531 E:1539 ||| VB
remission  ||| S:1539 E:1549 ||| NNS
( ||| S:1549 E:1550 ||| -LRB-
HDRS  ||| S:1550 E:1555 ||| NNP
score  ||| S:1555 E:1561 ||| NN
? ||| S:1561 E:1562 ||| CD
7 ||| S:1562 E:1563 ||| CD
)  ||| S:1563 E:1565 ||| -RRB-
of  ||| S:1565 E:1568 ||| IN
moderate  ||| S:1568 E:1577 ||| JJ
to  ||| S:1577 E:1580 ||| TO
severe  ||| S:1580 E:1587 ||| JJ
depression  ||| S:1587 E:1598 ||| NN
within  ||| S:1598 E:1605 ||| IN
six  ||| S:1605 E:1609 ||| CD
months ||| S:1609 E:1615 ||| NNS
,  ||| S:1615 E:1617 ||| ,
compared  ||| S:1617 E:1626 ||| VBN
with  ||| S:1626 E:1631 ||| IN
citalopram  ||| S:1631 E:1642 ||| JJ
monotherapy ||| S:1642 E:1653 ||| NN
.  ||| S:1653 E:1655 ||| .
The  ||| S:1655 E:1659 ||| DT
endpoints  ||| S:1659 E:1669 ||| NN
will  ||| S:1669 E:1674 ||| MD
be  ||| S:1674 E:1677 ||| VB
the  ||| S:1677 E:1681 ||| DT
reduction  ||| S:1681 E:1691 ||| NN
in  ||| S:1691 E:1694 ||| IN
HDRS  ||| S:1694 E:1699 ||| NNP
score  ||| S:1699 E:1705 ||| NN
after  ||| S:1705 E:1711 ||| IN
4  ||| S:1711 E:1713 ||| CD
weeks  ||| S:1713 E:1719 ||| NNS
of  ||| S:1719 E:1722 ||| IN
treatment ||| S:1722 E:1731 ||| NN
,  ||| S:1731 E:1733 ||| ,
and  ||| S:1733 E:1737 ||| CC
the  ||| S:1737 E:1741 ||| DT
HDRS  ||| S:1741 E:1746 ||| NNP
score  ||| S:1746 E:1752 ||| NN
after  ||| S:1752 E:1758 ||| IN
26  ||| S:1758 E:1761 ||| CD
weeks  ||| S:1761 E:1767 ||| NNS
of  ||| S:1767 E:1770 ||| IN
treatment ||| S:1770 E:1779 ||| NN
.  ||| S:1779 E:1781 ||| .
The  ||| S:1781 E:1785 ||| DT
study  ||| S:1785 E:1791 ||| NN
will  ||| S:1791 E:1796 ||| MD
enrol  ||| S:1796 E:1802 ||| VB
452  ||| S:1802 E:1806 ||| CD
participants  ||| S:1806 E:1819 ||| NNS
from  ||| S:1819 E:1824 ||| IN
general  ||| S:1824 E:1832 ||| JJ
practices  ||| S:1832 E:1842 ||| NNS
who  ||| S:1842 E:1846 ||| WP
have  ||| S:1846 E:1851 ||| VBP
a  ||| S:1851 E:1853 ||| DT
moderate  ||| S:1853 E:1862 ||| JJ
or  ||| S:1862 E:1865 ||| CC
severe ||| S:1865 E:1871 ||| JJ
,  ||| S:1871 E:1873 ||| ,
current  ||| S:1873 E:1881 ||| JJ
or  ||| S:1881 E:1884 ||| CC
recurrent  ||| S:1884 E:1894 ||| JJ
major  ||| S:1894 E:1900 ||| JJ
depressive  ||| S:1900 E:1911 ||| JJ
episode  ||| S:1911 E:1919 ||| NN
when  ||| S:1919 E:1924 ||| WRB
medication  ||| S:1924 E:1935 ||| NN
with  ||| S:1935 E:1940 ||| IN
an  ||| S:1940 E:1943 ||| DT
SSRI  ||| S:1943 E:1948 ||| NNP
is  ||| S:1948 E:1951 ||| VBZ
considered ||| S:1951 E:1961 ||| VBN
.  ||| S:1961 E:1963 ||| .
The  ||| S:1963 E:1967 ||| DT
study  ||| S:1967 E:1973 ||| NN
population  ||| S:1973 E:1984 ||| NN
will  ||| S:1984 E:1989 ||| MD
be  ||| S:1989 E:1992 ||| VB
stratified  ||| S:1992 E:2003 ||| VBN
according  ||| S:2003 E:2013 ||| VBG
to  ||| S:2013 E:2016 ||| TO
age ||| S:2016 E:2019 ||| NN
,  ||| S:2019 E:2021 ||| ,
sex ||| S:2021 E:2024 ||| NN
,  ||| S:2024 E:2026 ||| ,
HDRS  ||| S:2026 E:2031 ||| NNP
score ||| S:2031 E:2036 ||| NN
,  ||| S:2036 E:2038 ||| ,
age  ||| S:2038 E:2042 ||| NN
of  ||| S:2042 E:2045 ||| IN
onset  ||| S:2045 E:2051 ||| NN
of  ||| S:2051 E:2054 ||| IN
first  ||| S:2054 E:2060 ||| JJ
episode ||| S:2060 E:2067 ||| NN
,  ||| S:2067 E:2069 ||| ,
number  ||| S:2069 E:2076 ||| NN
of  ||| S:2076 E:2079 ||| IN
previous  ||| S:2079 E:2088 ||| JJ
depressive  ||| S:2088 E:2099 ||| JJ
episodes  ||| S:2099 E:2108 ||| NNS
and  ||| S:2108 E:2112 ||| CC
duration  ||| S:2112 E:2121 ||| NN
of  ||| S:2121 E:2124 ||| IN
current  ||| S:2124 E:2132 ||| JJ
episode ||| S:2132 E:2139 ||| NN
.  ||| S:2139 E:2141 ||| .
The  ||| S:2141 E:2145 ||| DT
population  ||| S:2145 E:2156 ||| NN
will  ||| S:2156 E:2161 ||| MD
then  ||| S:2161 E:2166 ||| RB
be  ||| S:2166 E:2169 ||| VB
randomised  ||| S:2169 E:2180 ||| VBN
into  ||| S:2180 E:2185 ||| IN
two  ||| S:2185 E:2189 ||| CD
groups ||| S:2189 E:2195 ||| NNS
.  ||| S:2195 E:2197 ||| .
Subjects  ||| S:2197 E:2206 ||| NNS
will  ||| S:2206 E:2211 ||| MD
be  ||| S:2211 E:2214 ||| VB
interviewed  ||| S:2214 E:2226 ||| VBN
to  ||| S:2226 E:2229 ||| TO
determine  ||| S:2229 E:2239 ||| VB
HDRS  ||| S:2239 E:2244 ||| JJ
score ||| S:2244 E:2249 ||| NN
,  ||| S:2249 E:2251 ||| ,
measure  ||| S:2251 E:2259 ||| NN
blood  ||| S:2259 E:2265 ||| NN
pressure ||| S:2265 E:2273 ||| NN
,  ||| S:2273 E:2275 ||| ,
count  ||| S:2275 E:2281 ||| NN
pills  ||| S:2281 E:2287 ||| NNS
and  ||| S:2287 E:2291 ||| CC
discuss  ||| S:2291 E:2299 ||| VB
side-effects ||| S:2299 E:2311 ||| JJ
.  ||| S:2311 E:2313 ||| .
This  ||| S:2313 E:2318 ||| DT
will  ||| S:2318 E:2323 ||| MD
occur  ||| S:2323 E:2329 ||| VB
weekly  ||| S:2329 E:2336 ||| JJ
for  ||| S:2336 E:2340 ||| IN
the  ||| S:2340 E:2344 ||| DT
first  ||| S:2344 E:2350 ||| JJ
four  ||| S:2350 E:2355 ||| CD
weeks ||| S:2355 E:2360 ||| NNS
,  ||| S:2360 E:2362 ||| ,
and  ||| S:2362 E:2366 ||| CC
every  ||| S:2366 E:2372 ||| DT
four  ||| S:2372 E:2377 ||| CD
weeks  ||| S:2377 E:2383 ||| NNS
thereafter ||| S:2383 E:2393 ||| RB
.  ||| S:2393 E:2395 ||| .
